Etelcalcetide CAS:1262780-97-1

Etelcalcetide is primarily used to manage secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) who are on hemodialysis. SHPT is a common complication of CKD characterized by excessive secretion of parathyroid hormone (PTH) from the parathyroid glands in response to decreased calcium levels due to impaired kidney function. Etelcalcetide acts as a calcimimetic, meaning it mimics the effects of calcium at the calcium-sensing receptors (CaSR) on the parathyroid gland. By activating these receptors, etelcalcetide reduces PTH secretion. Elevated PTH levels in CKD can lead to bone disorders and cardiovascular complications, so controlling PTH levels is crucial for managing the health of patients on hemodialysis. The administration of etelcalcetide typically occurs intravenously at the end of hemodialysis sessions, making it convenient for patients undergoing regular dialysis treatments. Clinical studies have shown that etelcalcetide effectively lowers PTH levels in CKD patients, helping to maintain calcium-phosphorus balance and reduce the risk of related complications like bone mineral disorders. In addition to its role in managing SHPT, etelcalcetide may also contribute to improving cardiovascular outcomes in CKD patients by addressing mineral and bone disorders associated with elevated PTH levels. Ongoing research continues to explore its potential benefits and optimal use in different stages of CKD, aiming to enhance the overall management and quality of life for patients undergoing hemodialysis.